GlassScriptPhysician profile
Bradley J Luttrell
NPI 1508850298
$3,651.15
in general payments reported to CMS, 2019-2025
20 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $295 · 2021: $346 · 2022: $405 · 2023: $471 · 2024: $626 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,177.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $683.38 | 2019-2025 | Tecnis Iol, Veritas Vision System |
| Alcon Vision LLC | $617.99 | 2019-2025 | Clareon, Argos, Centurion |
| Tarsus Pharmaceuticals, INC. | $398.72 | 2024-2025 | Xdemvy |
| Abbvie INC. | $258.83 | 2022-2025 | |
| Ivantis, INC | $204.91 | 2020-2021 | |
| Biotissue Holdings INC. | $193.86 | 2022-2024 | |
| Apellis Pharmaceuticals, INC. | $178.92 | 2025 | Syfovre |
| Mallinckrodt Hospital Products INC. | $177.59 | 2021-2025 | Acthar |
| Aerie Pharmaceuticals, INC. | $151.00 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $132.60 | 2019-2025 | Cequa |
| Rxsight INC | $121.30 | 2022-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Oyster Point Pharma, INC. | $101.17 | 2023-2025 | Tyrvaya |
| Carl Zeiss Meditec USA, INC. | $97.96 | 2021-2023 | Quatera 700 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $97.28 | 2019-2021 | |
| Allergan, INC. | $93.64 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Cataract Technology INC. | $38.88 | 2022 | |
| Bausch & Lomb Americas INC. | $38.38 | 2022-2023 | Vyzulta |
| Horizon Therapeutics Plc | $36.14 | 2021-2023 | Tepezza |
| Dompe US, INC. | $15.25 | 2025 | Oxervate |
| Harrow Eye, LLC | $13.35 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Luttrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.